Industry leaders discuss how to improve the speed, precision and cost-effectiveness of clinical exome testing for newborn screening and rare and undiagnosed diseases
Clinical exome testing is revolutionizing the diagnosis of rare and inherited diseases. Its ability to quickly pinpoint the genetic causes of complex conditions has made it a critical component of personalized medicine, leading to earlier diagnoses, targeted treatments and improved patient outcomes. However, without the right strategies, databases and informatics tools, clinical exome testing remains inaccessible for many small to mid-sized laboratories.
The Third Annual Clinical Hereditary Disease Diagnostics Summit hosted by QIAGEN Digital Insights will examine the incredible opportunities—and challenges—of brining clinical exome testing in-house. Join industry leaders as they discuss how labs, regardless of size, budget and experience, can integrate exome testing into routine clinical care with transformative impact for providers and their patients.
Featured topics will include:
